ReviewDermatology and therapy2021
Mast Cell Stabilizers in the Treatment of Rosacea: A Review of Existing and Emerging Therapies.
Review in Dermatology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06307288 (Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Neurogenic Rosacea and Facial Dysesthesia: Neurovascular-Immune Mechanisms and Translational Therapeutic Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.Cureus · 2026Review
- Transcriptomic and metabolomic insights into gabapentin's therapeutic role in neurogenic inflammation of rosacea.Communications biology · 2026Article
- Ameliorative effects and mechanisms of paeonol against rosacea through network pharmacology and experimental validation.Frontiers in immunology · 2026Article
- Beyond the boundaries of pigmentation and inflammation: understanding the mechanistic basis of melasma-rosacea comorbidity.Frontiers in medicine · 2026Review
- Topical Remibrutinib Attenuates LL37-Induced Rosacea-Like Dermatitis by Inhibiting BTK Activation, NF-κB Signaling and Mast Cell Activation.Journal of inflammation research · 2026Article
- Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea.Frontiers in immunology · 2026Article
- Novel Thermosensitive Hydrogel Encapsulated Carvedilol for the Treatment of Rosacea.ACS omega · 2025Article
- LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.Frontiers in immunology · 2025Article
- No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study.Ewha medical journal · 2025Article
- Rosacea in Older Adults and Pharmacologic Treatments.Drugs & aging · 2024Review
- Knowledge, attitudes and practices regarding spinal vascular malformations among doctors in China: a cross-sectional study.BMJ open · 2024Article
- Rosacea: Practical Guidance and Challenges for Clinical Management.Clinical, cosmetic and investigational dermatology · 2024Review
- Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.Frontiers in medicine · 2023Review
- Chlorogenic Acid Isomers Isolated fromBiomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosacea is a chronic inflammatory skin disease characterized by centrofacial erythema, papules, pustules, and telangiectasias. The onset of rosacea typically occurs after 30 years of age. It is estimated that approximately 2-5% of adults worldwide are affected. While the exact etiology of rosacea remains unknown, its pathogenesis is thought to be multifactorial with both environmental and genetic factors implicated. Ultraviolet radiation, heat, steam, ingested agents, including spicy foods and alcohol, host vasculature, dermal matrix degeneration, genetic susceptibility, and microbial organisms, including Demodex mites and Heliobacter pylori, have been implicated in the development of rosacea. Recently, mast cells (MCs) have emerged as key players in the pathogenesis of rosacea through the release of pro-inflammatory cytokines, chemokines, proteases, and antimicrobial peptides leading to cutaneous vasodilation, angiogenesis, and tissue fibrosis. Several existing and emerging topical, oral, and injectable therapeutics have been associated with improvement of rosacea symptoms based on their ability to stabilize and downregulate activated MCs. Herein, we review the data implicating MCs in the pathogenesis of rosacea and discuss interventions that may stabilize this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.